1689 – Quantification of NT-proBNP in patients with systemic sclerosis, and in patients with diagnosed pulmonary arterial hypertension

Page last updated: 28 October 2022

Application Detail

Description of Medical Service

Measurement of NT-proBNP (also known as N-terminal pro-brain natriuretic peptide, N-terminal pro-B-type natriuretic peptide or N-terminal prohormone of brain natriuretic peptide) through a blood test. The blood test is intended to enable the early detection of systemic sclerosis related pulmonary arterial hypertension, and be used as a regular assessment of pulmonary arterial hypertension disease progression.

Description of Medical Condition

Systemic sclerosis (scleroderma) is a multi-organ autoimmune disease characterised by vasculopathy (disease affecting blood vessels) and fibrosis (thickening and scarring of connective tissue). Patients with systemic sclerosis are at an increased risk of pulmonary arterial hypertension. Pulmonary arterial hypertension is characterised by increased pulmonary vascular resistance (resistance against blood flow), and may be idiopathic (arising from an unknown cause), or due to other underlying factors or disease associations such as connective tissue disease.

Reason for Application

New MBS item

Medical Service Type

Investigative technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 5357 KB)
Application Form (Word 11392 KB)

Consultation Survey

Consultation Survey (PDF 692 KB)
Consultation Survey (Word 72 KB)

PASC Consultation
PASC consultation closed

MSAC Consultation
MSAC consultation input closed Friday, 10 June 2022.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

PICO Confirmation (PDF 2256 KB)
PICO Confirmation (Word 7761 KB)

Assessment Report


Public Summary Document

Public Summary Document (PDF 1006 KB)
Public Summary Document (Word 631 KB)

Meetings for this Application


9-10 December 2021


9-10 June 2022


28-29 July 2022